喘息・COPD用装置の世界市場-2023年～2030年

概要

世界の喘息・COPD用装置市場は、2022年に412億米ドルに達し、2023～2030年の予測期間中にCAGR 4.5％で成長し、2030年には612億米ドルに達すると予測されています。

喘息は気道の炎症と腫脹を引き起こし、その結果、肺に酸素を運ぶ気道が狭くなります。喘息と慢性閉塞性肺疾患（COPD）は、口から直接肺に薬を送り込むハンドヘルド型吸入器で治療されます。吸入器の種類には、加圧式定量吸入器、ドライパウダー吸入器、ソフトミスト吸入器などがあります。

さらに、技術的進歩の増加、製品の発売、喘息やCOPDに対する意識の高まりといった重要な成長促進要因が、将来の市場成長をもたらします。グラクソ・スミスクライン社、ノバルティス社、アストラゼネカ社、ファイザー社、Lepu Medical Technology Co.Ltd.など、その他の活動も活発に行われています。

ダイナミクス

喘息・COPD用装置の製品上市の増加

吸入器と噴霧器（ネブライザー）は、吸入薬が喘息とCOPDの治療に使用される2つの主な方法です。大手企業による製品の上市は市場成長の原動力となり、これらの効果的な研究開発は製品の上市に役立つだけでなく、新しい治療法を発見し、何百万人もの喘息やCOPDの症状を持つ人々のケアを改善します。

例えば、2023年8月、ViatrisとKindevaドラッグデリバリーLPは、アストラゼネカのSymbicortの初のジェネリック医薬品であるBreyna（ブデソニド・フォルモテロールフマル酸塩二水和物）吸入エアゾールを発売しました。ブレイナは、喘息または慢性閉塞性肺疾患（COPD）の特定の患者を適応症とする薬剤・デバイス配合剤です。適応は6歳以上の喘息患者です。

さらに、2022年5月、世界喘息デーのテーマ「Closing Gaps In Asthma Carte」に沿って、Alkem Laboratories社は、喘息・COPD患者の生活を容易にするDPIデバイスであるInnohalerを発売しました。したがって、上記の要因により、市場は予測期間中に拡大すると予想されます。

喘息やCOPDに対する意識の高まりが喘息・COPD用装置市場を後押し

世界の喘息・COPD用装置市場は、喘息およびCOPDの状態に対する認識の高まりにより、近年大きな成長を遂げています。政府機関や民間団体が喘息やCOPDの啓発活動を行うことで、喫煙や化学物質への曝露のリスクを理解することができます。また、症状がある人が早期に治療を受けるのに役立ち、その人の寿命を改善する可能性さえあります。

例えば、2022年4月、VillageMDとCOPD財団は、Village Medicalの診療所における慢性閉塞性肺疾患（COPD）の特定と治療を改善するためのパートナーシップを宣言しました。このパートナーシップは、教育や患者へのアウトリーチキャンペーンを通じて認識を高め、未診断のCOPD患者を特定し、肺リハビリテーションへのアクセスを増やすことを目的としています。

さらに2020年5月、フロリダ州保健省は5月を「全米喘息啓発月間」と定め、喘息患者の生活改善に向けた診断・治療プログラムについてフロリダ州民に啓蒙する機会を設けています。フロリダ州保健省は、喘息ケアへの包括的なアプローチの一環として、オーダーメイドの書面による喘息行動計画（AAP）の使用を促進することにより、喘息を持つフロリダ州民とその家族の生活をより良いものにするために、国および州全体のパートナーと協力しています。

噴霧器に伴う副作用が市場の成長を妨げる

噴霧器の使用による副作用には、皮膚の発疹、かゆみ、じんましん、顔、唇、舌、のどの腫れなどのアレルギー反応があります。また、心拍リズムの変化、速い心拍や不規則な心拍、めまい、気が遠くなったりふらついたりする感じ、胸の痛み、呼吸困難につながることもあります。噴霧器の使用は、血圧を上昇させ、筋肉のけいれんや痛みを引き起こすこともあります。したがって、上記の要因は市場の成長を妨げると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 喘息・COPD用装置の上市の増加
    • 喘息・COPDに対する意識の高まり
  • 抑制要因
    • 噴霧器に伴う副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析
• DMIの見解

第6章 COVID-19分析

第7章 製品別

• 吸入器
  • 乾式吸入器
  • 定量吸入器
  • ソフトミスト吸入器
• 噴霧器
  • コンプレッサー噴霧器
  • メッシュ噴霧器
  • 超音波噴霧器

第8章 流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な動向と戦略

第11章 企業プロファイル

• GlaxoSmithKline Plc.
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Novartis AG
• AstraZeneca Plc.
• Pfizer Inc.
• Lepu Medical Technology Co. Ltd.
• Omron Healthcare Co. Ltd.
• Trudell Medical International
• Beurer GmbH
• Merck KGaA
• PARI GmbH

第12章 付録

Overview

Global Asthma and COPD Devices Market reached US$ 41.2 billion in 2022 and is expected to reach US$ 61.2 billion by 2030 growing with a CAGR of 4.5% during the forecast period 2023-2030.

Asthma causes inflammation and swelling of the airways and it results in narrowing of the airways that carry oxygen to the lungs. Asthma and Chronic Obstructive Pulmonary Disease (COPD) are treated with handheld inhalers that deliver medicine directly to the lungs through the mouth. Types of inhaler devices include pressurized metered dose inhalers, dry powder inhalers, and soft mist inhalers.

Furthermore, significant growth drivers such as increasing technological advancements, product launches, and rising awareness for asthma and COPD give rise to future market growth. Significant key players like GlaxoSmithKline Plc., Novartis AG, AstraZeneca Plc., Pfizer Inc., Lepu Medical Technology Co. Ltd., and others are actively operating in the market.

Dynamics

Increasing Product Launches for Asthma and COPD Devices

Inhalers and nebulizers are the two main ways inhaled medicine is used to treat asthma and COPD. The product launches by major companies help to drive market growth and these effective research and developments help in product launches and also finding new treatments and improve care for millions of people with asthma and COPD conditions.

For instance, in August 2023, Viatris and Kindeva Drug Delivery LP launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the first generic version of AstraZeneca's Symbicort. Breyna is a drug-device combination product that is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD). It is indicated for asthma patients of 6 years and above.

Additionally, in May 2022, in line with the theme of World Asthma Day " Closing Gaps In Asthma Carte", Alkem Laboratories launched Innohaler, a DPI device to make life easier for Asthma and COPD patients. Hence, due to the above factors, the market is expected to boost over the forecast period.

Rising Awareness for Asthma and COPD is Boosting the Asthma and COPD Devices Market

The global asthma and COPD devices market has witnessed significant growth in recent years due to the rising awareness of asthma and COPD conditions. Awareness conducted by government and private organizations for asthma and COPD helps people understand the risks of smoking and chemical exposure. It also helps people with symptoms to seek treatment earlier and could even improve a person's life expectancy.

For instance, in April 2022, VillageMD and the COPD Foundation declared a partnership to better identify and treat chronic obstructive pulmonary disease (COPD) at Village Medical practices. This partnership aims to raise awareness through education and outreach campaigns to patients help identify those with undiagnosed COPD, and increase access to pulmonary rehabilitation.

Additionally, in May 2020, The Florida Department of Health recognizes May as National Asthma Awareness Month and takes the opportunity to educate Floridians regarding diagnosis and treatment programs committed to improving the lives of those living with asthma. The department is working with national and statewide partners to make life better for Floridians with asthma and their families by promoting the use of a tailored, written asthma action plan (AAP) as part of a comprehensive approach to asthma care.

Side Effects Associated with Nebulizer Will Hamper the Growth of the Market

Side effects of using a nebulizer include allergic reactions such as skin rash, itching, hives, and swelling of the face, lips, tongue, or throat. It can also lead to heart rhythm changes, fast or irregular heartbeat, dizziness, feeling faint or lightheaded, chest pain, and trouble breathing. Using of nebulizer can also increase blood pressure and cause muscle cramps or pain. Thus, the above factors are expected to hamper the market growth.

Segment Analysis

The global asthma and COPD devices market is segmented based on product, distribution channel, and region.

Asthma inhalers are hand-held, portable devices that deliver medication to the lungs. Doctors suggest the use of inhaled corticosteroids (ICS) to prevent asthma symptoms along with a rescue inhaler for quick relief of attacks. Inhalers are expected to hold the largest market share over the period forecast owing to increasing product launches.

For instance, in July 2023, Teva UK launched a new GoResp Digihaler system in the United Kingdom. GoResp Digihaler is the first integrated inhaler device with built-in sensors that detect and record objective data on the patient's use and ability to use their inhaler including inspiratory flow classification.

Additionally, in July 2023, Hormosan Pharma GmbH, a wholly-owned subsidiary of the Lupin company in Germany, launched Luforbec, a pressurized metered dose inhaler in the European nation. Luforbec is indicated for adult asthma and COPD treatment, where the use of an inhaled corticosteroid and long-acting beta2-agonist is suitable.

Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share in 2022

The global asthma and COPD devices market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. North America has maintained a significant proportion of the asthma and COPD devices market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising prevalence and incidence of asthma conditions, and product approvals in asthma and COPD devices.

For instance, according to the Asthma and Allergy Foundation of America 2023, nearly 26 million people in the U.S. have asthma and this equals about 1 in 13 people. Nearly 21 million U.S. adults ages 18 and older have asthma. Asthma is more common in female adults than in male adults. Around 9.7% of female adults have asthma, compared to 6.2% of male adults.

Additionally, in January 2023, Airsupra (albuterol/budesonide) was approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide.

Competitive Landscape

The major global players in the market include: GlaxoSmithKline Plc., Novartis AG, AstraZeneca Plc., Pfizer Inc., Lepu Medical Technology Co. Ltd., Omron Healthcare Co. Ltd., Trudell Medical International, Beurer GmbH, Merck KGaA, PARI GmbH among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the global asthma and COPD devices market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular check-ups, appointments, device launches, and consultations worldwide. Many hospitals are focused on COVID-19 cases, and this reduces asthma and COPD diagnoses in many patients suffering from these chronic diseases.

Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the asthma and COPD devices market is expected to be moderately affected over the forecast period.

By Product

• Inhalers

  Dry Powered Inhalers

  Metered Dose Inhalers

  Soft Mist Inhalers

• Nebulizers

  Compressor Nebulizer

  Mesh Nebulizer

  Ultrasonic Nebulizer

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

By Region

• North America

  U.S.

  Canada

  Mexico

• Europe

  Germany

  U.K.

  France

  Italy

  Spain

  Rest of Europe

• South America

  Brazil

  Argentina

  Rest of South America

• Asia-Pacific

  China

  India

  Japan

  Australia

  Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In January 2023, Synergy Life Science, Inc. developed Nebi which is the first pocket-sized and fully battery-operated nebulizer for use in a variety of applications. Nebi is powered by a rechargeable battery and is small enough to fit into a pocket or purse allowing easy access to nebulizer therapies.
• In February 2023, Aptar Pharma, launched the HeroTracker Sense, a novel digital respiratory health solution that transforms a standard metered dose inhaler (pMDI) into a smart connected healthcare device. HeroTracker Sense is a next-generation metered-dose inhaler (MDI) add-on connected device, designed to address patient inhalation technique and adherence.
• In May 2023, South Africa by the Allergy Foundation of South Africa (AFSA) launched a new device called the AfriSpacer which makes inhalation of medication from an asthma pump easier and far more effective.

Why Purchase the Report?

• To visualize the global asthma and COPD devices market segmentation based on product, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global asthma and COPD devices market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global asthma and COPD devices market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by Distribution Channel
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Product Launches for Asthma and COPD Devices
    • 4.1.1.2. Rising Awareness for Asthma and COPD
  • 4.1.2. Restraints
    • 4.1.2.1. Side Effects Associated with Nebulizer
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis
• 5.5. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. By Product

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 7.1.2. Market Attractiveness Index, By Product
• 7.2. Inhalers
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Dry Powered Inhalers
  • 7.2.4. Metered Dose Inhalers
  • 7.2.5. Soft Mist Inhalers
• 7.3. Nebulizers
  • 7.3.1. Compressor Nebulizer
  • 7.3.2. Mesh Nebulizer
  • 7.3.3. Ultrasonic Nebulizer

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacy
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Online Pharmacy
• 8.4. Retail Pharmacy

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Product Benchmarking
• 10.3. Company Share Analysis
• 10.4. Key Developments and Strategies

11. Company Profiles

• 11.1. GlaxoSmithKline Plc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Novartis AG
• 11.3. AstraZeneca Plc.
• 11.4. Pfizer Inc.
• 11.5. Lepu Medical Technology Co. Ltd.
• 11.6. Omron Healthcare Co. Ltd.
• 11.7. Trudell Medical International
• 11.8. Beurer GmbH
• 11.9. Merck KGaA
• 11.10. PARI GmbH

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us